Opposing effects of low versus high concentrations of vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs)

Study Abstract

Colorectal cancer is one of the global causes of cancer deaths. Cancer stem cells (CSCs) inside the tumour niche responsible for metastasis and relapses, and hence need to be targeted for cancer therapeutics. Although dietary fibre and lifestyle changes have been recommended as measures for colorectal cancer prevention, no such recommendations are available for using water soluble vitamins as prophylaxis measure for colorectal cancers. **High dose of Vitamin C has been proven to selectively kill colon cancer cells having BRAF and KRAS mutations by inducing oxidative stress. In this study, we show for the first time the opposing effects of the low and high dose of Vitamin C and vitamin B3 on colon CSCs isolated from HT-29 and HCT-15 colorectal carcinoma cell lines.** At small doses, both of these vitamins exerted a cell proliferative effect only on CSCs, while there was no change in the proliferation status of non-stem cancer cells and wild-type (WT) populations. On the other hand, the death effects induced by high doses of Vitamin C and B3 were of the order of 50–60% and ~30% on CSCs from HT-29 and HCT15, respectively. Interestingly, the control fibroblast cell line (NIH3T3) was highly refractory all the tested concentrations of Vitamin C and B3, except for the highest dose – 10,000μg of Vitamin C that induced only 15% of cell death. Hence, these results indicate the future scope of use of therapeutic doses of Vitamin C and B3 especially in patients with advanced colorectal cancer.

### Cell types and percentage of cell proliferation

<table>
<thead>
<tr>
<th>Vitamin C conc. µM</th>
<th>HT-29 WT</th>
<th>HCT-15 WT</th>
<th>HT-29-CD44+</th>
<th>HCT-15 CD44+</th>
<th>HT-29-CD44−</th>
<th>HCT-15 CD44−</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>5</td>
<td>114</td>
<td>108</td>
<td>172</td>
<td>107</td>
<td>86</td>
<td>122</td>
</tr>
<tr>
<td>10</td>
<td>104.7</td>
<td>114</td>
<td>160.8</td>
<td>107.26</td>
<td>93.11</td>
<td>121.01</td>
</tr>
<tr>
<td>15</td>
<td>95.81</td>
<td>121.03</td>
<td>172</td>
<td>110.15</td>
<td>97.1</td>
<td>106</td>
</tr>
<tr>
<td>20</td>
<td>90.57</td>
<td>94.19</td>
<td>169.73</td>
<td>115.01</td>
<td>99.2</td>
<td>93.79</td>
</tr>
<tr>
<td>25</td>
<td>88.48</td>
<td>90.01</td>
<td>169.73</td>
<td>116.32</td>
<td>86.59</td>
<td>98.13</td>
</tr>
<tr>
<td>100</td>
<td>21.51</td>
<td>89.01</td>
<td>68.28</td>
<td>93.79</td>
<td>14.23</td>
<td>96.15</td>
</tr>
<tr>
<td>200</td>
<td>21.81</td>
<td>88.06</td>
<td>69.34</td>
<td>73.58</td>
<td>14.13</td>
<td>96.52</td>
</tr>
<tr>
<td>500</td>
<td>23.56</td>
<td>85.42</td>
<td>67.23</td>
<td>72.01</td>
<td>12.68</td>
<td>95.16</td>
</tr>
<tr>
<td>1,000</td>
<td>24.34</td>
<td>83.12</td>
<td>65.81</td>
<td>69.56</td>
<td>11.59</td>
<td>88.06</td>
</tr>
<tr>
<td>10,000</td>
<td>27.06</td>
<td>226</td>
<td>61.18</td>
<td>304.10</td>
<td>14.13</td>
<td>233.03</td>
</tr>
</tbody>
</table>

Table 2. Percentage of cell proliferation upon exposure to low (5–25µM) and high concentration ranges (100–10,000µM) of vitamin C/ascorbic acid in various cell populations obtained from HT-29 and HCT-15 colorectal carcinoma cell lines respectively. Table showing the respective percentages of cell proliferation of the cell populations WT, CSCs (CD44+) and non-stem cancer cells (CD44−) with respect to various concentrations (5–10,000µM) of Vitamin C/Vitamin C from HT-29 and HCT-15 cell lines. The untreated control cells for each of the cell type WT, CSCs (CD44+) and non-stem cancer cells (CD44−) have been assigned an arbitrary value of 100% cell proliferation.
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

Daniel Couturier wrote: “I cannot comprehend why even proponents of high dose vitamin C consider it to be an inferior resource when it comes to antagonizing malignancies, considering the fact that available studies indicate that at doses of 4 g / kg b.w. a pancreatic tumor mass reduction of more than 40% could be achieved in a xenograft animal model. “

Study Abstract

Ascorbic acid is an essential nutrient commonly regarded as an antioxidant. In this study, we showed that ascorbate at pharmacologic concentrations was a prooxidant, generating hydrogen-peroxide-dependent cytotoxicity toward a variety of cancer cells in vitro without adversely affecting normal cells. To test this action in vivo, normal oral tight control was bypassed by parenteral ascorbate administration. Real-time microdialysis sampling in mice bearing glioblastoma xenografts showed that a single pharmacologic dose of ascorbate produced sustained ascorbate radical and hydrogen peroxide formation selectively within interstitial fluids of tumors but not in blood. Moreover, a regimen of daily pharmacologic ascorbate treatment significantly decreased growth rates of ovarian (P < 0.005), pancreatic (P < 0.05), and glioblastoma (P < 0.001) tumors established in mice. Similar pharmacologic concentrations were readily achieved in humans given ascorbate intravenously. These data suggest that ascorbate as a prodrug may have benefits in cancers with poor prognosis and limited therapeutic options.

PMCID: PMC2516281 Qi Chen,*† Michael Graham Espey,*†‡ Andrew Y. Sun,* Chaya Pooput,§ Kenneth L. Kirk,§ Murali C. Krishna,¶ Deena Beneda Khosh,‖ Jeanne Drisko,‖ and Mark Levine*‡      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516281/
Antioxidant intake from diet and supplements and risk of digestive cancers in middle-aged adults: results from the prospective NutriNet-Santé cohort.

“Healthcare professionals may promote intake of these antioxidants in healthy amounts in order to reduce the incidence of this type of malignancy.”

Study Abstract

The results of the study showed that increased dietary levels of antioxidants such as vitamin C, E, β-carotene, and selenium are associated with lower risk of developing colon cancer. This important study has demonstrated the link between antioxidants and digestive cancer risk. The harmful effects of alcohol and smoking are also apparently reduced by the intake of selenium and vitamin E, respectively. Overall, antioxidants in the diet may reduce the risk of developing gastrointestinal cancers. Healthcare professionals may promote intake of these antioxidants in healthy amounts in order to reduce the incidence of this type of malignancy.

Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration.

Linus Pauling and his associate, Ewan Cameron, MD, did not claim that vitamin C cured cancer, only that it extended lives making the patient feel better. This Korean study supports the Pauling /Cameron claim of longer and better lives for terminal cancer patients.

Study Abstract

Over the years there has been a great deal of controversy on the effect of vitamin C on cancer. To investigate the effects of vitamin C on cancer patients' health-related quality of life, we prospectively studied 39 terminal cancer patients. All patients were given an intravenous administration of 10 g vitamin C twice with a 3-day interval and an oral intake of 4 g vitamin C daily for a week. And then we investigated demographic data and assessed changes in patients' quality of life after administration of vitamin C. Quality of life was assessed with EORTC QLQ-C30. In the global health/quality of life scale, health score improved from 36+/-18 to 55+/-16 after administration of vitamin C (p=0.001). In functional scale, the patients reported significantly higher scores for physical, role, emotional, and cognitive function after administration of vitamin C (p<0.05). In symptom scale, the patients reported significantly lower scores for fatigue, nausea/vomiting, pain, and appetite loss after administration of vitamin C (p<0.005). The other function and symptom scales were not significantly changed after administration of vitamin C. In terminal cancer patients, the quality of life is as important as cure. Although there is still controversy regarding anticancer effects of vitamin C, the use of vitamin C is considered a safe and effective therapy to improve the quality of life of terminal cancer patients.

PMID:17297243
PMCID: PMC2693571
10.3346/jkms.2007.22.1.7

Vitamin C - a new player in regulation of the cancer epigenome.

Study Abstract

Over the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their central roles in carcinogenesis. In hematological cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), drugs that reverse epigenetic aberrations are now the standard of care. Recent in vitro studies suggest that vitamin C at physiological concentrations, combined with hypomethylating agents may act synergistically to cause DNA demethylation through active and passive mechanisms, respectively. Additionally, several recent studies have renewed interest in the use of pharmacological doses of vitamin C injected intravenously to selectively kill tumour cells. This review will focus on the potential of vitamin C to optimize the outcome of epigenetic therapy in cancer patients and alternatively to act as a therapeutic at high doses.

PMID: 29102482
DOI: 10.1016/j.semcancer.2017.11.001

Unexpected Early Response in Oral Bioavailability of Vitamin C

Average IV & Average Oral Vitamin C

IV 7-19-2015 & Oral 7-26-2015